Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Zyme Communications

19:11 EDT 20th June 2018 | BioPortfolio

Here are the most relevant search results for "Zyme Communications" found in our extensive news archives from over 250 global news sources.

More Information about Zyme Communications on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zyme Communications for you to read. Along with our medical data and news we also list Zyme Communications Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zyme Communications Companies for you to search.

Showing News Articles 1–25 of 323 from Zyme Communications

Tuesday 19th June 2018

Enamine and TBD Biodiscovery collaborate to provide GMP-based services - Collaboration combines expertise in novel chemical compound synthesis with GMP manufacture in drug discovery

Kiev, Ukraine, and Tartu, Estonia, June 19th 2018. Enamine Ltd., a chemical research organization and producer of novel building blocks and screening libraries, and TBD Biodiscovery, a premium GMP manufacturer of fine chemicals including chemical active pharmaceutical ingredients (APIs), today announced they have entered into a collaboration agreement. The partnership aims to manage the trans...

Optibrium Introduces StarDrop 6.5

Novel features include modelling for drug metabolism prediction and virtual library enumeration Enhanced data visualisation environment for more efficient data analysis and project management CAMBRIDGE, UK, 19 June, 2018 – Optibrium™, a developer of software for drug discovery, today announced the launch of version 6.5 of StarDrop™ that provides a complete platform...

Monday 18th June 2018

Avacta Group plc announces the appointment of Dr Eliot Forster as Non-Executive Chairman

Highly experienced pharma/biotech professional to lead Avacta’s Board Wetherby and Cambridge, UK, 11 June 2018: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce the appointment of Dr Eliot Forster as Non-Executive Chairman to the Board with immediate effect.  Dr Trevor Nichols, who has acted as Chairman of the Board ...

Wednesday 13th June 2018

Mologic and Newcastle University launch BReD diagnostic for blackgrass resistance at Cereals

Rapid, one-step, lateral flow test for real-time detection of herbicide resistance in blackgrass Bedfordshire and Newcastle, UK, 13 June 2018: Mologic Ltd, a developer of personalised diagnostics, and Newcastle University, today announced they have developed an on-farm blackgrass resistance diagnostic (BReD). The one-step, rapid lateral flow product for detecting glutathione transferase (Am...

Tuesday 5th June 2018

IONTAS signs collaboration agreement with LG Chem, Ltd. to identify therapeutic oncology leads.

Cambridge, UK and Seoul, Korea, 05 June 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced it has signed a collaboration agreement with Korean-based LG Chem, Ltd. for the discovery of therapeutic antibodies targeting undisclosed targets for use in the treatment of cancers. Under the agreement IONTAS will use its proprietary ant...

Fujifilm completes acquisition of Irvine Scientific Sales Company and IS Japan, leading companies of cell culture media

SANTA ANA, California 05 June, 2018: FUJIFILM Corporation (President: Kenji Sukeno) announced today that it has completed the acquisition of Irvine Scientific Sales Company, Inc. (ISUS) and IS JAPAN CO.,LTD. (ISJ), leading companies in cell culture media for about US$800 million on June 1 in the United States. To advance its growth strategies in the healthcare area, Fujifilm continues to inves...

Monday 4th June 2018

New REAL Space Navigator Breaks Billion Compound Barrier - Enamine and BioSolveIT collaboration exceeds expectations to deliver 3.8bn new compounds on demand

Kiev, Ukraine, and Sankt Augustin, Germany, 04 June 2018. Enamine Ltd., a leading compound supplier and BioSolveIT GmbH, a premium provider of drug discovery software, today announced the availability of the next generation of REAL Space Navigator, an efficient search tool within the world’s largest purchasable chemical space. Originally launched in February this year, Version 2 of REAL...

Wednesday 30th May 2018

IONTAS awarded £556K ($737K) from Innovate UK to develop therapies for chronic pain management

Funding will be used to further develop IONTAS’ ion-channel targeting KnotBody antibody platform to block pain transmission via Nav1.7 Cambridge, UK, 30 May 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced today that it has been awarded a major grant to support ongoing research into its novel antibody platform, KnotBody&tra...

Thursday 24th May 2018

Bio-Rad Launches a Range of Anti-idiotypic Antibodies Targeting Pembrolizumab and Nivolumab

HERCULES, Calif.–May 24, 2018 –Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of a range of anti-idiotypic antibodies targeting the immune checkpoint inhibitor drugs: pembrolizumab (Keytruda) and nivolumab (Opdivo). Anti-pembrolizumab and anti-nivolumab antibodies are designed f...

Tuesday 22nd May 2018

Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT Biotech

Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits Wetherby and Cambridge, UK, 22 May 2018: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that its research collaboration with FIT Biotech Oy (FITBIO:FN Finland) has successfully completed a proof-of-concept study ...

Wednesday 16th May 2018

BIA Separations and Biomay collaborate on production and purification of large DNA plasmids

Collaboration enables high yield, high purity supercoiled plasmid DNA manufacture for therapeutic application Ajdovšcina, Slovenia and Vienna, Austria, 16 May 2018: BIA Separations, a leading biochromatography development and manufacturing company, and Biomay, a contact manufacturer of cGMP biopharmaceuticals, today announced a collaboration on the high-yield production of large DNA ...

Tuesday 15th May 2018

PhoreMost completes $15M (£11M) Series-A round to enter drug discovery - Investment to fund expansion of operations and progression of drug target pipeline

Cambridge, UK, 15 May 2018: PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has completed an £11m ($15m) Series-A investment round. The investment will be used to expand operations on the Babraham Research Campus and progress several novel drug targets from its next-generation “SITESEEKER®&rd...

Applied Photophysics signs agreements with Alfatest and Paralab to expand distribution in Europe

Distributors will supply Chirascan circular dichroism spectrometers and SX stopped-flow spectrometers to Italy, Portugal and Spain Surrey (UK), Rome (Italy) and Valbom (Portugal) – May 15, 2018: Applied Photophysics, a leading provider of systems for biophysical characterization of biomolecules, today announced that it has signed distribution agreements with scientific equipment distr...

Bio-Rad Introduces Anti-Vedolizumab Antibodies - Antibodies Used to Support Research into the Treatment of Ulcerative Colitis and Crohn’s Disease

HERCULES, Calif.–May 15, 2018–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the release of a range of anti-vedolizumab antibodies. Vedolizumab (Entyvio) is a monoclonal antibody that is used to treat ulcerative colitis (inflammatory bowel disease) and Crohn’s disease. Bio-Rad&rsqu...

Wednesday 9th May 2018

SYGNIS introduces 2view unique Western blot detection technology

Offers two modes of detection from a single antibody Fast visible detection of analytes at nanogram level Enhanced chemi-luminescence detection down to picogram level Easy to use with a single incubation Heidelberg, Germany and Cambridge, UK, 09 May 2018 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), today announced the introduction of 2view™,...

TTP plc and Camena Bioscience partner to create novel metabolite analyser

Cambridge, UK, 09 May 2018: TTP Plc (TTP), a leading independent technology and product development company, and Camena Bioscience, a developer of pioneering technology that profiles small molecules, such as metabolites, nutrients or medicines in liquid samples, announced today that they are collaborating to develop an instrument to monitor the health of cell cultures. The new instrument will...

Tuesday 8th May 2018

Horizon Discovery appoints Terry Pizzie as Chief Executive Office

Cambridge, UK, 08 May 2018: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or "the Company"), a global leader in gene editing and gene modulation technologies, is pleased to announce the appointment of Terry Pizzie as Chief Executive Officer and Board Director with immediate effect. Terry joined Horizon Discovery in 2017 as Head of Commercial Op...

SYGNIS completes acquisition of TGR Biosciences

Heidelberg, Germany and Cambridge, UK, 08 May 2018 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the completion of the acquisition of TGR Biosciences (TGR), the Australian research reagents company. TGR and its highly complementary technologies and products along with its strong customer base will significantly contribute to the overall performance of...

Wednesday 2nd May 2018

IONTAS and aTen Therapeutics announce collaboration to discover therapeutic oncology leads

Cambridge, UK and Edinburgh, UK, 02 May 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, and aTen Therapeutics Limited (aTen), a private biopharmaceutical company developing next-generation antibodies for the treatment of cancer, announced today that they have entered into a strategic collaboration. Under the agreement IONTAS will use its pr...

Tuesday 1st May 2018

Mologic Signs Agreements with Medisur and Peripal to Distribute PERiPLEX POC Diagnostic in Europe

Point-of-care test for detection of infection in patients on peritoneal dialysis available in France, Germany, Italy, The Netherlands, Austria and Switzerland Bedfordshire, UK, 1st May 2018: Mologic Ltd, a developer of powerful, personalised diagnostics to improve the lives of patients, today announced that it has signed agreements with medical technology companies, Medisur and Peripal AG t...

Monday 30th April 2018

Glythera appoints Professor Kerry Chester to SAB - Appointment supports the development of the Company’s pipeline

Newcastle, UK, 30th April, 2018: Glythera Limited (Glythera), the next-generation antibody drug conjugate (ADC) development company, today announces that it has appointed Professor Kerry Chester to its Scientific Advisory Board (SAB). Professor Chester’s appointment strengthens the Company’s SAB and will help shape its portfolio of ADCs for targeting previously untreatable cancers...

Tuesday 24th April 2018

Concept Life Sciences appoints Matilda Bingham as Site Director and David Higton as Biotransformation and Metabolite Identification Expert, at its Alderley Park site

Appointments support expansion of expertise in integrated drug discovery and development Manchester, UK, 24 April 2018: Concept Life Sciences (Concept), the integrated drug discovery, development and analytical services company, today announced it has appointed Matilda Bingham as Site Director of its Alderley Park site in Cheshire, UK, and David Higton as Principal Scientist (Biotransformat...

Monday 23rd April 2018

Cobra Biologics Receives the Queen’s Award for Enterprise in International Trade in the export of services for gene and immunotherapy products

The UK’s most prestigious business award granted in recognition of outstanding achievement in the export of services for gene and immunotherapy products. 21 April 2018, Keele, UK: Cobra Biologics (“Cobra”) a leading international contract development and manufacturing organisation (“CDMO”), today announced that it has been awarded the Queen’s Award 2018 f...

British Breast Cancer Company, Endomag, Wins Queen’s Award - UK company providing more accurate tools for breast cancer removal receives prestigious business award

Cambridge, UK, 21 April 2018: Endomag, the surgical guidance company, today announced it has received the Queen’s Award for Enterprise in Innovation for 2018. The Award recognises the Company’s efforts in developing novel surgical tools for more accurate removal of breast cancer. Endomag has developed a minimally invasive surgical guidance system, using its expertise in magnetic...

Wednesday 18th April 2018

Fusion Pharmaceuticals Licenses Isogenica’s CIS Display Technology - Technology will be used to progress Fusion’s pipeline of alpha therapeutics for the treatment of cancers

   Cambridge, UK and Hamilton, Canada, 18th April 2018: Isogenica Ltd and Fusion Pharmaceuticals Inc (Fusion) today announced a new licensing agreement that will leverage each other’s strengths in recombinant protein technologies and radiopharmaceutical development. Isogenica is a leader in the design and c


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks